656 related articles for article (PubMed ID: 24461901)
1. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
[TBL] [Abstract][Full Text] [Related]
4. Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.
Wechsler ME; Yawn BP; Fuhlbrigge AL; Pace WD; Pencina MJ; Doros G; Kazani S; Raby BA; Lanzillotti J; Madison S; Israel E;
JAMA; 2015 Oct; 314(16):1720-30. PubMed ID: 26505596
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®).
Vogelmeier CF; Asijee GM; Kupas K; Beeh KM
Adv Ther; 2015 Jun; 32(6):537-47. PubMed ID: 26100349
[TBL] [Abstract][Full Text] [Related]
6. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
7. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
8. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.
Bleecker ER; Postma DS; Lawrance RM; Meyers DA; Ambrose HJ; Goldman M
Lancet; 2007 Dec; 370(9605):2118-25. PubMed ID: 18156033
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
11. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
12. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
13. Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.
Bonini M; Permaul P; Kulkarni T; Kazani S; Segal A; Sorkness CA; Wechsler ME; Israel E
Am J Respir Crit Care Med; 2013 Dec; 188(12):1407-12. PubMed ID: 24228710
[TBL] [Abstract][Full Text] [Related]
14. Association of beta2-adrenoreceptor genotypes with bronchodilatory effect of tiotropium in COPD.
Umeda N; Yoshikawa T; Kanazawa H; Hirata K; Fujimoto S
Respirology; 2008 May; 13(3):346-52. PubMed ID: 18399855
[TBL] [Abstract][Full Text] [Related]
15. Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.
Yancey SW; Klotsman M; Ortega HG; Edwards LD; Anderson WH
Curr Med Res Opin; 2009 Apr; 25(4):1011-8. PubMed ID: 19275519
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
[TBL] [Abstract][Full Text] [Related]
17. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.
Wechsler ME; Kunselman SJ; Chinchilli VM; Bleecker E; Boushey HA; Calhoun WJ; Ameredes BT; Castro M; Craig TJ; Denlinger L; Fahy JV; Jarjour N; Kazani S; Kim S; Kraft M; Lazarus SC; Lemanske RF; Markezich A; Martin RJ; Permaul P; Peters SP; Ramsdell J; Sorkness CA; Sutherland ER; Szefler SJ; Walter MJ; Wasserman SI; Israel E;
Lancet; 2009 Nov; 374(9703):1754-64. PubMed ID: 19932356
[TBL] [Abstract][Full Text] [Related]
18. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Vogelmeier CF; Bateman ED; Pallante J; Alagappan VK; D'Andrea P; Chen H; Banerji D
Lancet Respir Med; 2013 Mar; 1(1):51-60. PubMed ID: 24321804
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.
Hodder R; Kesten S; Menjoge S; Viel K
Int J Chron Obstruct Pulmon Dis; 2007; 2(2):157-67. PubMed ID: 18044688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
